CorMedix reported third-quarter revenue of $54.5 million, adjusted EBITDA of $3.1 million and $355 million cash. It maintained 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million.
CRMD · CorMedix Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
CorMedix expects its proposed acquisition of substantially all Heron Therapeutics assets to close in the first quarter of 2027. Third-quarter revenue was $54.5 million and adjusted EBITDA was $3.1 million; 2026 revenue guidance remained $325 million to $345 million.
CorMedix Inc. expects to close its acquisition of substantially all Heron Therapeutics assets in the first quarter of 2027, targeting $125 to $150 million of revenue in 2027 and $45 to $60 million of annualized operating cost synergies.
CorMedix agreed to acquire substantially all of Heron Therapeutics’ assets, adding four commercial-stage products—ZYNRELEF, APONVIE, CINVANTI and SUSTOL—for $145.0 million cash and 14,583,333 shares. Closing is expected in the first quarter of 2027.
CorMedix reported third-quarter revenue of $54.5 million, net loss of $14.7 million and adjusted EBITDA of $3.1 million. For its pending Heron asset acquisition, a term loan provides up to $150 million, with $75 million expected at closing.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. Bullish, management expects the 2027 DefenCath add-on to exceed $2.37 each quarter, Heron to add approximately $125 to $150 million of pro forma revenue and generate $45 to $60 million of synergies, and reported Q3 revenue above consensus alongside $355 million of cash; 2026 guidance was reaffirmed and Rezeo received priority FDA review. Bearish, average 2027 DefenCath reimbursement is expected below $8.32, 2027 DefenCath guidance is deferred, TPN enrollment is behind schedule, and Medicare Advantage contracting, LDO pilot orders and Azzerty litigation and competition remain unresolved risks.
- + The DefenCath add-on is expected to exceed $2.37 in every quarter of 2027, with an average at least double the current rate.
- + The acquired Heron products are expected to contribute approximately $125 to $150 million of pro forma 2027 revenue, roughly doubling the non-DefenCath revenue base.
- + Management reaffirmed 2026 revenue guidance of $325 to $345 million and narrowed adjusted EBITDA guidance to $130 to $140 million.
- + Third-quarter revenue was $54.5 million and above consensus, with adjusted EBITDA of $3.1 million and $355 million of cash.
- + The Rezeo prophylaxis application was accepted for FDA review with priority review status and a target action date in the first quarter of 2027.
- + The Heron transaction is expected to generate $45 to $60 million of annualized operating cost synergies by the end of 2027.
- − Average 2027 reimbursement for DefenCath is expected to be lower than $8.32 over the course of the year.
- − The Phase III TPN study enrollment is tracking meaningfully behind the original timetable.
- − The Medicare Advantage contractual framework was not largely final, and operationalization hurdles remained.
- − The LDO pilot had not generated repeat orders.
- − The Heron revenue range is exposed to the Azzerty litigation and the risk of a competing branded launch.
- − Management deferred 2027 DefenCath guidance pending visibility into pricing, utilization and Medicare Advantage upside.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | $131.87M | For the Nine Months Ended September 30, 2026 | — |
| DefenCath | $17,181 | the three months ended September 30, 2026 filing | — |
| DefenCath net revenue | $17.18M | FY2026 Q3 | -80.6% |
|
|
|||
| EBITDA (Non-GAAP) non-GAAP | $109.21M | For the Nine Months Ended September 30, 2026 | — |
| Melinta Portfolio | $31,441 | the three months ended September 30, 2026 filing | — |
| Net proceeds from 2024 ATM program | $10.1M | the three months ended September 30, 2026 filing | — |
|
|
|||
| Sales Allowances | $267.6M | the three months ended September 30, 2026 filing | +239.6% |
|
|
|||
| sales of DefenCath | 17.2M | third quarter of 2026 | — |
| Shares of common stock sold under the 2024 ATM program | 1.3M | the three months ended September 30, 2026 filing | — |
| Melinta portfolio net revenue | $35.8M | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRMD
this stock
CorMedix Inc.
|
$357.92M | -61.3% | +617.0% | — | 17.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 29
CorMedix reported third-quarter revenue of $54.5 million, adjusted EBITDA of $3.1 million and $355 million cash. It maintained 2026 revenue guidance of $325 million to $345 million and narrowed adjusted EBITDA guidance to $130 million to $140 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRMD | -15.1% | -42.2% | -46.7% | -21.0% | -61.3% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -11.2% | -36.7% | -43.2% | -17.6% | -68.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.